FibroBiologics, Inc. (FBLG)
NASDAQ: FBLG · Real-Time Price · USD
0.3401
-0.0001 (-0.03%)
At close: Mar 12, 2026, 4:00 PM EDT
0.3500
+0.0099 (2.91%)
After-hours: Mar 12, 2026, 6:51 PM EDT
Company Description
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases.
The company’s product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis.
It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers.
FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
FibroBiologics, Inc.
| Country | United States |
| Founded | 2021 |
| IPO Date | Jan 31, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Peter O’Heeron |
Contact Details
Address: 455 East Medical Center Boulevard, Suite 300 Houston, Texas 77598 United States | |
| Phone | 281 671 5150 |
| Website | fibrobiologics.com |
Stock Details
| Ticker Symbol | FBLG |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $30.00 |
| CIK Code | 1958777 |
| CUSIP Number | 31573L105 |
| ISIN Number | US31573L1052 |
| Employer ID | 86-3329066 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Peter O'Heeron | Founder, Chairperson and Chief Executive Officer |
| Dr. Hamid Khoja Ph.D. | Chief Scientific Officer |
| Ruben A. Garcia J.D. | General Counsel |
| Jason D. Davis CPA | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 6, 2026 | 8-K | Current Report |
| Feb 24, 2026 | 10-K | Annual Report |
| Feb 23, 2026 | 8-K | Current Report |
| Feb 6, 2026 | 8-K | Current Report |
| Jan 2, 2026 | 8-K | Current Report |
| Dec 30, 2025 | EFFECT | Notice of Effectiveness |
| Dec 30, 2025 | 424B3 | Prospectus |
| Dec 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Dec 29, 2025 | DEF 14A | Other definitive proxy statements |
| Dec 23, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |